• Haleon halted imports of Centrum's OTC-registered products into China until further notice following a raw material classification change.
• The affected products generated approximately £75 million in FY 2025 revenue.
• Food-registered Centrum products remain unaffected; the classification change was unrelated to product quality or safety.
• FY 2026 organic revenue growth is now expected around 2.5%, incorporating the China disruption and Brazil distribution changes.
• Brazil's rollout will accelerate to coincide with its new tax framework, reducing fourth-quarter net revenue by approximately £15 million–£20 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HALEON plc published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.